We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

PD-L1: A Therapeutic Target for Malignant Melanomas in Dogs

News   Apr 23, 2021 | Original story from Hokkaido University

 
PD-L1: A Therapeutic Target for Malignant Melanomas in Dogs

Antitumor effect of anti-PD-L1 antibody. CT images of oral malignant melanoma (upper left) and its lung metastases (lower left) observed in a Pomeranian (12 years old, male). As a result of treatment with anti-PD-L1 antibody, all detectable tumors disappeared (right panels). Credit: Naoya Maekawa, et al

 
 
Advertisement
 

RELATED ARTICLES

Initial Immune Response Key to Preventing Pandemics

News

New research suggests that a host's initial immune response has a central role in determining whether infection occurs and the degree to which it spreads within a population.

READ MORE

New Technology Transports the Genes for Therapeutic Agents Directly Into Tumor Cells

News

A new technology from UZH researchers enables the body to produce therapeutic agents on demand at exactly the point where they are needed. The innovation could reduce the side effects of cancer therapy and help better deliver COVID-19 treatments to the lungs.

READ MORE

Improving the Quality and Safety of Heparin

News

A team has analyzed Heparin, the blood-thinning drug, using a new method to that can pinpoint contaminants more accurately and quickly, providing greater quality control and safety.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE